^
9d
Phase classification
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
over2years
Trial completion • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
3years
KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1b, N=169, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
almost4years
KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1b, N=169, Active, not recruiting, Astellas Pharma Global Development, Inc. | N=300 --> 169 | Trial completion date: Feb 2023 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Aug 2021
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
4years
Clinical • Enrollment closed • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
over4years
KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1b, N=300, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2022 --> Feb 2023 | Trial primary completion date: Jul 2021 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
over4years
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=6, Completed, Astellas Pharma Inc | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2020 | Trial primary completion date: Dec 2022 --> Jun 2020
Clinical • Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
ASP8374
almost5years
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=6, Active, not recruiting, Astellas Pharma Inc | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Checkpoint inhibition
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK mutation
|
ASP8374